Remicade: Biosimilars And Pricing Pressure Wear On J&J's Blockbuster Brand

US sales were down 14%, but much of the hit was due to a 2016 price adjustment that was felt across the pharma portfolio, and execs insisted the impact of biosimilars is more moderate than expected.